Flagship R&D facility for Adaptimmune
Enlarge image


Flagship R&D facility for Adaptimmune

07.10.2015 - T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major R&D facility for 200 staff.

The company is one of Britain’s biotech success stories: “We started up Adaptimmune as three people on Milton Park in 2008 to research into engineered T-cell receptors to fight cancer,” says Adaptimmune CEO James Noble. Meanwhile, the company employs more than 150 staff, and it is making space for even more. The company’s expanding R&D will find a new home in a flagship facility to be built in Adaptimmune’s home Milton Park.

According to the company, construction of the 6,200 square metre purpose-built facility is already under way. The “Enterprise Zone” facility will house around 200 R&D staff, with laboratory space and associated offices as well as meeting rooms and a café. Adaptimmune has signed a 25-year lease with the business park’s owner MEPC. “We are delighted to be working closely with MEPC on this exciting new building, which will provide best-in-class laboratories to support the expansion of our R&D team and enable continuing progress with our research programmes,” said James Noble, Chief Executive Officer of Adaptimmune.

Adaptimmune has rapidly expanded its clinical programmes over the last few years. The Oxford-headquartered company is currently running five Phase I/II trials in multiple cancers across the US, targeting the NY-ESO-1 cancer antigen in both solid and haematological cancers. Earlier this year, Adaptimmune pulled off a €157m IPO on NASDAQ. “Adaptimmune was established at Milton Park in 2008 in a small laboratory, and we have watched this pioneering company expand into a globally recognised business,” commented James Dipple, CEO of MEPC Milton Park. “We are delighted that we are able to accommodate their growth plans by building a bespoke, state of the art new building.”


Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).

© 2007-2015 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLMED (I)0.37 EUR8.82%


  • THERAMETRICS (CH)0.05 CHF-16.67%
  • MDX HEALTH (B)3.50 EUR-14.84%


  • CHRONTECH PHARMA (S)0.36 SEK3500.0%
  • THROMBOGENICS (B)4.16 EUR48.0%
  • OREXO (S)66.75 SEK36.5%


  • TRANSGENE (F)2.78 EUR-43.6%
  • NEOVACS (F)0.69 EUR-24.2%


  • KARO BIO (S)44.20 SEK5161.9%
  • CHRONTECH PHARMA (S)0.36 SEK414.3%
  • GALAPAGOS (B)41.63 EUR258.0%


  • NEOVACS (F)0.69 EUR-78.6%
  • BIOTEST (D)19.45 EUR-74.5%
  • EVOCUTIS (UK)0.16 GBP-71.9%

No liability assumed, Date: 06.10.2015